LITFULO™
(ritlecitinib) PFIZER
HK Reg. No. HK-68283 (28 Jun, 2024)
Composition:4
LITFULO™ is a kinase inhibitor available in the form of capsule with 50 mg ritlecitinib.
Indication:4
LITFULO™ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK (Janus kinase) inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
References
1. TARGRETIN®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 2. AKEEGA™. Package Insert 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 3. LEQEMBI®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf 4. LITFULO™. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
